Yervoy
Opdivo/Yervoy combo secures FDA approval for malignant pleural mesothelioma
October 6, 2020Manufacturing and Production, Research and Development Bristol-Myers Squibb, Yervoy, bristol myers squibb, opdivo
Bristol Myers Squibb’s therapy regimen of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) has secured FDA approval for the first-line …
Bristol-Myers Squibb demonstrates potential for long-term survival in kidney cancer patients treated with Opdivo plus Yervoy
February 20, 2020Business Services Cancer, Cancers, Yervoy, opdivo, renacl cell carcinoma, renal cancer
Bristol-Myers Squibb has announced updated results from trialing Opdivo (nivolumab) plus Yervoy (ipilimumab) versus sunitinib in patients with previously untreated …
BMS pulls Opdivo+Yervoy combo in EU for advanced non-small cell lung cancer
February 3, 2020Sales and Marketing BMS, Cancer, Europe, Yervoy, lung cancer, opdivo
Bristol-Myers Squibb has confirmed it has withdrawn its application with the European Commission for its combination of Opdivo (nivolumab) and …
BMS’ Opdivo+Yervoy+Chemo combo shows superior overall survival in first-line lung cancer
October 23, 2019Research and Development Bristol-Myers Squibb, Cancer, NSCLC, Yervoy, lung cancer, opdivo, pharma
Bristol Myers Squibb has lifted the curtain on new Phase 3 data for its blockbuster immunotherapy Opdivo (nivolumab), showing that …
BMS Opdivo/Yervoy recommended for untreated kidney cancer via Cancer Drugs Fund
April 5, 2019Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, Kidney cancer, NICE, UK, Yervoy, opdivo
NICE has revealed it is recommending that Bristol-Myers Squibb’s Opdivo (nivolumab), in combination with Yervoy (ipilimumab), be made available to …
Bristol-Myers Squibb withdraws lung cancer combo therapy marketing application
January 25, 2019Medical Communications BMS, Merck, Yervoy, ctla4, lung cancer, opdivo
Bristol-Myers Squibb has been forced to withdraw a marketing application for its combination of Opdivo and Yervoy for lung cancer. …
BMS’ Opdivo+Yervoy combo fails in small cell lung cancer
November 27, 2018Manufacturing and Production, Research and Development Bristol-Myers Squibb, Cancer, Yervoy, lung cancer, opdivo, pharma
Bristol-Myers Squibb has revealed that its combo comprising Opdivo (nivolumab) and Yervoy (ipilimumab) failed to meet its primary endpoint as …
BMS’ Opdivo and Yervoy combination shows outstanding survival rate in cancer patients
October 22, 2018Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Yervoy, melanoma, opdivo
American pharma firm Bristol-Myers Squibb have announced that more than 53% of patients with advanced melanoma, who were treated with …
BMS’ Opdivo+Yervoy combo secures FDA approval in kidney cancer
April 18, 2018Research and Development, Sales and Marketing BMS, Bristol Myers Swuibb, Cancer, FDA, Yervoy, carcinoma, opdivo, pharma
The FDA has announced its approval of a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), both products from Bristol Myers …
BMS’ Opdivo and Yervoy combo better than chemo in halting lung cancer progression
February 6, 2018Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, NSCLC, Yervoy, lung cancer, opdivo, pharma
Bristol-Myers Squibb has revealed promising data from its ongoing Phase 3 study investigating the efficacy of Opdivo (nivolumab) in combination …
Bristol-Myers Squibb’s Yervoy scores EU approval in paediatric melanoma
January 23, 2018Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, EU, Yervoy, pharma
Bristol-Myers Squibb has revealed that its immunotherapy Yervoy (ipilimumab) has received an expanded indication from the European Commission, approving the …
BMS left red-faced as Opdivo+Yervoy fails to beat rival Pfizer drug in kidney cancer
August 16, 2017Research and Development BMS, Kidney cancer, Yervoy, life sciences, opdivo, pharma, pharmaceutical
Bristol-Myers Squibb has been left somewhat red-faced after its combination of Opdivo (nivolumab) and Yervoy (ipilimumab) failed to show any …
Asia-Pacific NSCLC market to more than double to $6.2bn by 2023
March 21, 2017Manufacturing and Production, Research and Development, Sales and Marketing BMS, Eli Lilly, MSD, NSCLC, Yervoy, keytruda, opdivo
New research from intelligence provider GBI Research has indicated that the non-small cell lung cancer (NSCLC) market in the Asia-Pacific …
BMS shares promising Opdivo/Yervoy data for advanced bladder cancer
December 8, 2016Research and Development BMS, Yervoy, opdivo
BMS has revealed new efficacy data on the combination of its immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment …
BMS unveils reorganisation plans & boosted profits
October 28, 2016Business Services, Medical Communications Bristol-Myers Squibb, Yervoy, opdivo
BMS has announced its intention to restructure its operations alongside $3 billion share buyback and quarterly results which exceeded expectations.The …
